This is a mechanism module, not a specific disease. Disorder entries should reference individual nodes via conforms_to using "neuromuscular_transmission_failure#<Node Name>"; the key conformance target is "neuromuscular_transmission_failure#Loss of the Safety Factor of Neuromuscular Transmission", the disorder-agnostic rate-limiting step that every conformer funnels through regardless of whether the endplate lesion is genetic, autoimmune, or toxic. The two nodes upstream of it are deliberately a parallel pair rather than a chain — "Reduced Quantal Acetylcholine Release" is the presynaptic arm and "Reduced Postsynaptic Endplate Response to Acetylcholine" the postsynaptic arm — because which one a disorder engages is exactly the discriminating fact (Lambert-Eaton and botulism are presynaptic; acetylcholine-receptor myasthenia gravis and most congenital myasthenic syndromes are postsynaptic; endplate acetylcholinesterase deficiency and the glycosylation congenital myasthenic syndromes engage both). A conforming entry is expected to declare only the arm it actually uses. The generic cell types are motor neuron (CL:0000100) and skeletal muscle fibre (CL:0008002); conforming entries substitute the disease-relevant populations (cholinergic neuron for botulism, which also strikes autonomic cholinergic synapses outside the neuromuscular junction).
Boundaries with neighbouring modules. This module is deliberately complementary to — not a duplicate of — synaptic_vesicle_cycle, which models the release machinery itself (docking, priming, SNARE-mediated fusion, endocytic recycling) across all synapse types and is the right home for the presynaptic congenital myasthenic syndromes caused by vesicle-cycle genes such as UNC13A, SNAP25, SYT2 and VAMP1. A presynaptic conformer may legitimately declare conformance to both: synaptic_vesicle_cycle for the lesion in the release machine, this module for the endplate-specific consequence of that lesion on the safety factor. The module also does not model the muscle fibre's own excitability once the action potential has been generated — that is the skeletal-muscle channelopathy territory proposed as a separate trunk in issue #9005 — nor the motor neuron degeneration and reinnervation that follow chronic denervation.
Scope caveat worth carrying into conformers: the safety factor is not uniform across muscles. Ruff (PMID:22102453) explicitly excepts extraocular, middle ear, and some facial and pharyngeal muscles from the "slave synapse" description that holds for extremity and axial fibres, which is part of why ocular and bulbar muscles are preferentially affected in myasthenia gravis and botulism. Selective vulnerability is listed in #9005 as a domain-wide unexplained problem; this module records the non-uniformity rather than asserting a mechanism for it.
Module evidence is drawn from the primary safety-factor literature (PMID:11275359, PMID:22102453, PMID:18632162) plus review-level anchors for each etiologic arm that are already curated and cached in the conforming disorder entries. It is illustrative of the abstracted pattern rather than an exhaustive citation set. Created for the Tier-1 neuromuscular module layer requested in issue #9005.
Why is the safety factor not uniform across muscles, and what determines which muscle groups lose it first in a given endplate disease?
KNOWLEDGE GAP
nmj_safety_factor_selective_vulnerability
Attached to:
Intermittent Endplate Transmission Block
The module treats the safety factor as one scalar, which is what licenses the convergence claim, but the muscles that block first differ systematically between conformers — ocular and bulbar in myasthenia gravis and botulism, proximal lower limb in Lambert-Eaton myasthenic syndrome — and Ruff (PMID:22102453) explicitly excepts extraocular, middle ear, and some facial and pharyngeal muscles from the reliable "slave synapse" description that holds elsewhere. Candidate contributors include baseline differences in endplate geometry, receptor subunit composition, fibre type, firing rate, and the extent of the junctional folds, but no single account predicts the observed distributions across all three etiologic arms. This is the module-level instance of the domain-wide selective-vulnerability gap recorded in issue #9005, and it is a genuine absence of evidence rather than a model-fidelity problem, so it is a KNOWLEDGE_GAP rather than a HUMAN_MODEL_MISMATCH.
Endplate Component Lesion
trigger
The proximal lesion: loss, blockade, or kinetic alteration of a protein that the motor endplate depends on for reliable transmission. The lesion may sit at any of three locations. Presynaptic — acetylcholine synthesis (CHAT), vesicular loading, or the release apparatus, including the P/Q-type voltage-gated calcium channels that couple the nerve terminal action potential to release and the SNARE proteins cleaved by botulinum neurotoxin. Synaptic basal lamina — endplate acetylcholinesterase and its collagenic tail (COLQ), laminin beta-2 (LAMB2). Postsynaptic — the muscle nicotinic acetylcholine receptor subunits (CHRNA1, CHRNB1, CHRND, CHRNE), the clustering pathway that builds and maintains the endplate (AGRN, MUSK, LRP4, RAPSN, DOK7), the glycosylation enzymes those proteins depend on (GFPT1, DPAGT1, ALG2, ALG14), and the endplate Nav1.4 channels (SCN4A). Conforming entries substitute their specific lesion and its etiologic class: germline variant, autoantibody, or toxin.
Downstream
-
Reduced Quantal Acetylcholine Release
A presynaptic lesion — acetylcholine synthesis or vesicular loading, calcium entry, or the release machinery — lowers the number or content of quanta released per nerve impulse.
-
Reduced Postsynaptic Endplate Response to Acetylcholine
A postsynaptic or synaptic-basal-lamina lesion lowers the depolarization each released quantum produces, by reducing receptor number, altering channel kinetics, or simplifying endplate geometry.
Show evidence (4 references)
"Most CMS stem from molecular defects in the muscle nicotinic acetylcholine receptor, but they can also be caused by mutations in presynaptic proteins, mutations in proteins associated with the synaptic basal lamina, defects in endplate development and maintenance, or defects in protein glycosylation."
Enumerates the presynaptic, synaptic-basal-lamina and postsynaptic locations of the endplate lesion, which is the partition this trigger node abstracts.
"Myasthenia gravis is an autoimmune disease that is characterised by muscle weakness and fatigue, is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic..."
Establishes the autoimmune arm of the trigger: autoantibodies against postsynaptic endplate proteins are an alternative route to the same lesion.
"P/Q-type voltage-gated calcium channels (VGCCs) localized in the presynaptic motor nerve terminal and in the autonomic nervous system are targeted by antibodies in LEMS patients"
Establishes the presynaptic autoimmune arm of the trigger, in which the targeted endplate component is the calcium channel that gates release.
+ 1 more reference
Reduced Quantal Acetylcholine Release
amplifier
The presynaptic arm. The endplate potential amplitude is the product of the number of quanta released per nerve impulse and the depolarization each quantum produces; this node covers reduction of the first term. Quantal content falls when acetylcholine cannot be resynthesised or repackaged fast enough to keep up with activity (choline acetyltransferase deficiency, vesicular loading defects), when the presynaptic calcium signal that triggers release is reduced (loss of active-zone P/Q-type calcium channels), or when the release machinery itself is disabled (SNARE proteolysis by botulinum neurotoxin). Because the presynaptic terminal can be modulated on a moment-to-moment basis, this arm is the one that facilitates: brief maximal exercise or high-frequency stimulation transiently raises quantal content, which is why the Lambert-Eaton compound muscle action potential increments and the myasthenia gravis one does not.
Used by disorders
Botulism
as Presynaptic acetylcholine release blockade
Downstream
-
Loss of the Safety Factor of Neuromuscular Transmission
Fewer or less-filled quanta per impulse lower the endplate potential amplitude towards the muscle action potential threshold.
Show evidence (3 references)
"The amplitude of the EPP is a function of the number of acetylcholine (ACh) molecules per synaptic vesicle, the number of synaptic vesicles released by nerve impulse, and the efficacy of the released quanta."
Identifies quantal number and vesicular acetylcholine content as the presynaptic determinants of endplate potential amplitude, the quantity this node reduces.
"the presence of decrement and increment upon repetitive nerve stimulation is also a highly sensitive diagnostic test"
The post-exercise increment is the electrophysiological signature of a presynaptic release deficit that can be transiently overcome, distinguishing this arm from the postsynaptic one.
"The characteristic flaccid paralysis results from blocking acetylcholine transmission across the neuromuscular junction by inhibition of acetylcholine release from the presynaptic motor neuron terminal"
Shows the toxin route to the same presynaptic node, with paralysis attributed specifically to blocked acetylcholine release.
Reduced Postsynaptic Endplate Response to Acetylcholine
amplifier
The postsynaptic arm, covering the second term of the endplate potential: the depolarization produced per released quantum. It falls when acetylcholine receptors are lost from the junctional folds (complement-mediated lysis and antigenic modulation in acetylcholine-receptor myasthenia gravis; low-expressor receptor-subunit variants in congenital myasthenic syndromes), when receptor channel kinetics are abnormally fast so the synaptic current decays before threshold is reached (fast-channel syndromes), when clustering and maintenance of the endplate fail so the postsynaptic region is simplified and small (RAPSN, DOK7, MUSK, and the glycosylation syndromes), or when the endplate Nav1.4 channels that convert the endplate potential into an action potential are lost or inexcitable. In myasthenia gravis the last two act together: the same complement-mediated destruction of junctional folds removes both receptors and sodium channels, so the endplate potential shrinks while the threshold it must reach rises.
Downstream
-
Loss of the Safety Factor of Neuromuscular Transmission
A smaller endplate potential, a faster-decaying synaptic current, or a raised action-potential threshold all narrow the margin between the endplate potential and the depolarization needed to fire the fibre.
Show evidence (3 references)
"In intercostal nerve-muscle preparations from MG patients, we found that endplate AChR loss decreases the size of the endplate potential, and endplate Na(+) channel loss increases the threshold depolarization needed to produce a muscle action potential."
Endplate recordings from excised human intercostal nerve-muscle preparations showing both postsynaptic contributions this node models: a smaller endplate potential and a raised action-potential threshold.
"Postsynaptic AChRs and voltage-gated Na(+) channels are both lost from the neuromuscular junction in MG."
Establishes that the two postsynaptic determinants are lost together, which is why the autoimmune conformers engage this node on both counts.
"Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders characterized by impaired neuromuscular signal transmission due to germline pathogenic variants in genes expressed at the neuromuscular junction (NMJ)."
Establishes the genetic route into the same postsynaptic node, where the receptor and clustering genes are the largest class.
Loss of the Safety Factor of Neuromuscular Transmission
central effector
The central integrating step and the key conformance target. In health the endplate potential overshoots the depolarization needed to open the postsynaptic Nav1.4 channels by a factor of roughly three to five in adult mammals, so transmission is reliable under physiological stress. The safety factor is that excess, and it is a single scalar into which every upstream lesion feeds: quantal content, vesicular acetylcholine content, endplate acetylcholinesterase activity, receptor density and kinetics, endplate geometry, and sodium-channel density all enter it. This is what makes the module a module — a genetic receptor-subunit variant, a complement-fixing autoantibody, an anti-calcium-channel antibody and a clostridial protease are mechanistically unrelated up to this point and indistinguishable after it. Conforming entries substitute their own route into this node and inherit everything downstream of it.
Used by disorders
Botulism
as Somatic neuromuscular transmission failure
Downstream
-
Intermittent Endplate Transmission Block
Once the endplate potential no longer reliably exceeds threshold, individual nerve impulses begin to fail to produce a muscle action potential.
Show evidence (5 references)
"This is a result of the amount of transmitter released per nerve impulse being greater than that required to trigger an action potential in the muscle fibre. The safety factor is a measure of this excess of released transmitter."
Defines the safety factor as the excess of released transmitter over the trigger threshold, which is the quantity this node models the loss of.
"In normal adult mammals, the safety factor is generally 3-5."
Gives the normal margin, which is what the disease lesions in this module erode.
"Thus, both acquired autoimmune and inherited congenital diseases of the neuromuscular junction (NMJ) can significantly reduce, or even transiently increase, safety factor."
States the convergence claim on which the module rests: autoimmune and congenital endplate diseases act on the same scalar.
+ 2 more references
Intermittent Endplate Transmission Block
effector
The functional consequence. Transmission does not fail all-or-none across the muscle; it fails stochastically at individual endplates, and the blocked fraction grows as activity continues, because normal short-term synaptic depression reduces quantal content over the first few impulses of a train and there is no longer any margin to absorb it. This is what the standard diagnostic tests measure: a decremental compound muscle action potential on low-frequency repetitive nerve stimulation, and increased jitter and frank blocking on single-fibre electromyography. The node is deliberately separate from the safety factor node above it because it is where the disorder-specific distribution enters — which muscles block first, and under what activity pattern, differs between the conformers and is not a property of the safety factor itself.
Downstream
-
Fatigable Muscle Weakness
Loss of a growing fraction of muscle fibres from the activated pool during sustained or repeated contraction produces weakness that worsens with use.
Show evidence (2 references)
"Measurement of compound muscle action potentials elicited by repetitive nerve stimulation is required to diagnose CMS."
Identifies the repetitive-nerve-stimulation response as the measurement that detects this node, and as diagnostically required across the congenital arm.
"While the phenotypic presentation of these disorders is diverse, the unifying feature is a pathomechanism that disrupts neuromuscular transmission."
States the convergence at the level of disrupted transmission while noting that the clinical presentation stays disorder-specific, which is the division of labour between this node and the conforming entries.
Fatigable Muscle Weakness
consequence
The convergent clinical endpoint: weakness that fluctuates and worsens with sustained or repeated activity, and recovers with rest, because the fraction of endplates in block rises and falls with the activity history. Distribution, tempo, and severity are disorder-specific and stay on the conforming entries — ocular and bulbar onset with fatigable ptosis and diplopia in myasthenia gravis, proximal lower-limb weakness with hyporeflexia and autonomic involvement in Lambert-Eaton myasthenic syndrome, descending flaccid paralysis after cranial nerve palsies in botulism, and neonatal hypotonia, feeding difficulty or episodic apnoea in the congenital myasthenic syndromes. When enough endplates block simultaneously in the diaphragm and accessory muscles the endpoint is neuromuscular respiratory failure, which is the shared cause of death across all three etiologic arms.
Show evidence (3 references)
"Myasthenia gravis is an autoimmune disease that is characterised by muscle weakness and fatigue, is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic..."
Anchors the fatigable-weakness endpoint for the autoimmune postsynaptic arm.
"Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disease characterized by proximal muscle weakness, loss of tendon reflexes, and autonomic dysfunction"
Anchors the endpoint for the presynaptic autoimmune arm and records its distinct distribution, including the autonomic involvement that follows from the same lesion at non-neuromuscular cholinergic synapses.
"Botulism is a rare, neurotoxin-mediated, life-threatening disease characterized by flaccid descending paralysis that begins with cranial nerve palsies and might progress to extremity weakness and respiratory failure."
Anchors the endpoint for the toxin arm, including the respiratory failure that is the shared terminal risk across the module.
Acetylcholinesterase Inhibitor Therapy
Platform:
Small molecule
The canonical symptomatic treatment for endplate transmission failure and the module's core drug-target pattern. Inhibiting endplate acetylcholinesterase prolongs the dwell time of released acetylcholine in the synaptic cleft so that each quantum activates more receptors, raising endplate potential amplitude and restoring the safety factor without touching the underlying lesion. It is therefore effective across etiologically unrelated conformers — acquired autoimmune and inherited congenital alike — which is itself evidence for the convergence this module asserts. The important exception, and the reason this is a target-mechanism annotation rather than a blanket recommendation, is that conformers whose lesion is a depolarization block or an endplate myopathy (slow-channel syndrome, endplate acetylcholinesterase deficiency, DOK7 and LAMB2 congenital myasthenic syndromes) are worsened by it; a conforming entry must record its own direction of effect.
Evidence: 3
Presynaptic Potassium Channel Blockade (3,4-Diaminopyridine)
Platform:
Small molecule
The presynaptic counterpart of the acetylcholinesterase-inhibitor pattern. Blocking presynaptic voltage-gated potassium channels prolongs the nerve terminal action potential, increasing calcium entry and therefore the number of quanta released per impulse. It acts on the presynaptic arm rather than the postsynaptic one, which is why it is the mainstay in Lambert-Eaton myasthenic syndrome and an adjunct in the presynaptic and receptor-deficiency congenital myasthenic syndromes, and why it can be combined with an acetylcholinesterase inhibitor to act on both terms of the endplate potential at once.
Evidence: 2